Serologicals is creating a third division that will focus on bioprocessing, the company said Monday.
The group will include some 300 people. It will focus on research, development, manufacturing and commercialization of the company’s cell culture supplement and diagnostic products as well as contract research services.
David Bellitt has been named president of the new group. He previously led customer development efforts for Serologicals’ previous product lines.
“The creation of the Celliance division results from a recognition of the critical importance of our bioprocessing products and services to the ongoing growth and development of the Company,” said David Dodd, CEO of Serologicals, in a statement. “This will allow us to focus our resources and to be a better and more successful business partner with our customers, while confirming our long-term commitment to this business area, while placing it under the leadership of a focused and capable individual who will be instrumental in helping us meet and exceed future business objectives.”